OPKO Health (OPK) Misses Q3 EPS by 3c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
OPKO Health (OPK) Submitted PMA Application with FDA for Point-of-Care PSA Test with Claros 1 Platform
November 7, 2017 8:17 AM ESTOPKO Health, Inc. (NASDAQ: OPK) announces the filing of a Premarket Approval (PMA) application with the U.S. Food and Drug Administration (FDA) for the Total PSA test with the Claros® 1 immunoassay analyzer. The filing contains clinical data from the Companys 864-patient Total PSA clinical study.
The Claros 1 immunoassay analyzer is a novel diagnostic instrument system that can provide rapid, quantitative blood test results in 10 minutes right in the physicians office. The Claros 1 incorporates cutting edge microfluidics in a credit card sized disposable test... More
